Equities By Region UK Pharmaceuticals & Health

Shire share price: Takeda set to win EU approval for takeover deal

Share this article!

Japan’s drugmaker Takeda Pharmaceutical is set to win conditional EU antitrust approval for its $62-billion takeover of Shire (LON:SHP), Reuters has reported. The news comes with the European regulator scheduled to rule on the deal by November.

Shire’s share price rose marginally in the previous session, climbing 0.28 percent higher to close at 4,612.50p, while this morning, the stock has 2.38 percent to 4,722.50p as of 08:02 GMT, outperforming the broader UK market, with the benchmark FTSE 100 index currently standing 1.03 percent higher at 7,178.31 points. The group’s shares have added a little more than 50 percent to their value over the past year, as compared with about a 4.4-percent dip in the Footsie.

Takeda to win EU approval

Two people with knowledge of the matter told Reuters on Friday that Takeda was set to win conditional EU antitrust approval for its takeover of Shire, which would mark the biggest ever overseas acquisition by a Japanese company.

The new comes after the Japanese group recently proposed the sale of Shire’s prospective treatment for inflammatory bowel disease. The move followed discussions with the European Commission over  the future potential overlap in the area of inflammatory bowel disease between Takeda’s marketed product Entyvio and the UK group’s pipeline compound SHP647, which is currently in late-stage clinical trials. 

Reuters noted that the EU competition enforcer, which is scheduled to rule on the deal by November 20, and Takeda had declined to comment

Analysts on FTSE 100 pharmco

UBS reaffirmed its ‘neutral’ stance on Shire earlier this month, without specifying a price target on the shares. According to MarketBeat, the blue-chip group currently has a consensus ‘buy’ rating and an average price target of 4,725.30p.

As of 08:05 GMT, Monday, 12 November, Shire PLC share price is 4,755.50p.

Add Comment

Investing is speculative. When investing your capital is at risk. This site is not intended for use in jurisdictions in which the trading or investments described are prohibited and should only be used by such persons and in such ways as are legally permitted. Your investment may not qualify for investor protection in your country or state of residence, so please conduct your own due diligence. This website is free for you to use but we may receive commission from the companies we feature on this site. Click here for more information.